TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2607910
Drug: Fentanyl 3
Normalized name: FENTANYL 37.5MCG/HR PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 3 ug/kg plus aminophylline 3 mg/kg iv
Study: 31876900
Drug: Dupilumab 300
Normalized name: dupilumab 300 MG in 2 ML Auto-Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dupilumab 300 mg weekly or every 2 weeks
Study: 26454361
Drug: Dupilumab 300
Normalized name: dupilumab 300 MG in 2 ML Auto-Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dupilumab 300 mg every 4 weeks
Study: 31876900
Drug: Dupilumab 300
Normalized name: dupilumab 300 MG in 2 ML Auto-Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dupilumab 300 mg every 8 weeks
Study: 20490797
Drug: UFT (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFT (400 mg/m²/day for five consecutive days per week for 1 year)
Study: 17077073
Drug: HMB (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMB (3 g/d for 7 days)
Study: 14656658
Drug: Anterolateral (A‐L)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anterolateral (A‐L) THA
Study: 14656658
Drug: Posterolateral (P‐L)
Normalized name: p-L-Sarcolysin
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Posterolateral (P‐L) THA
Study: 14656658
Drug: Total THA
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total THA patients (A‐L and P‐L combined)
Study: 11500188
Drug: ACE inhibitors
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitors (lisinopril)
Study: 9228228
Drug: Ebastine 10
Normalized name: ebastine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ebastine 10 mg or 20 mg
Study: 26063762
Drug: Pharmacist prescribing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist prescribing (assessment of BP and cardiovascular risk, education on hypertension, prescribing of antihypertensive medications, laboratory monitoring, and monthly follow-up visits for 6 months)
Study: 18583285
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA) 300 mg/day
Study: 18583285
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA) 300 mg/day + Clopidogrel 75 mg/day
Study: 16567982
Drug: 2 doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses of 9VPCV
Study: 16567982
Drug: 1 dose
Normalized name: Ribose 3 GM/1 DOSE Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 dose of 9VPCV
Study: 14576714
Drug: Video lessons
Approvals — FDA: no, EMA: no, PMDA: no
Description: Video lessons (self-administered, video-lesson packets)
Study: 11089626
Drug: Circumcision in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Circumcision in HIV-positive men with viral loads <50,000 copies/ml
Study: 1333181
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg subcutaneous sumatriptan
Study: 1333181
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg subcutaneous sumatriptan
Study: 1322512
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg subcutaneous sumatriptan
Study: 1333181
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg subcutaneous sumatriptan
Study: 3881206
Drug: timolol, 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: timolol, 1 mg iv, followed by 1 mg doses at 20-min intervals
Study: 30614406
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (daily routines)
Study: 11923548
Drug: Inhaled fluticasone
Normalized name: fluticasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fluticasone propionate (FP) 750 microg bd
Study: 8596749
Drug: rHuEPO therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHuEPO therapy for 12 months
Study: 8834648
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (No-EPO group)
Study: 786961
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate (400 mcg/day)
Study: 27998692
Drug: Squill Oxymel
Normalized name: Squill oxymel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Squill Oxymel (10ml syrup, 2 times a day)
Study: 27998692
Drug: Simple oxymel
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simple oxymel (10ml syrup, 2 times a day)
Study: 25787895
Drug: DC loaded
Approvals — FDA: no, EMA: no, PMDA: no
Description: DC loaded with recombinant Prostate Specific Membrane Antigen (rPSMA) and recombinant Survivin (rSurvivin) peptides administered as a subcutaneous (s.c.) injection (5×10(6) cells)
Study: 25787895
Drug: Docetaxel (75 mg/m(2)
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel (75 mg/m(2) intravenous (i.v.)) and prednisone (5 mg, bis in die (b.i.d.))
Study: 21827648
Drug: Supervised walks
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Supervised walks of 30 minutes a day, 5 days a week as part of daily nursing care.
Study: 19413409
Drug: Patch treatment
Normalized name: DIMETHICONE 1.1 g in 100 mL TOPICAL LOTION [Dove DermaSeries Rough Patch Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patch treatment for smoking cessation
Study: 11180023
Drug: Rofecoxib 12.5
Normalized name: rofecoxib 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib 12.5 mg
Study: 11188492
Drug: Daily positive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily positive and negative affect
Study: 11188492
Drug: Daily nonwork
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily nonwork events (positive and negative)
Study: 11188492
Drug: Daily work
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily work events (positive and negative)
Study: 11188492
Drug: Lifetime symptoms
Normalized name: Pamprin Multi-Symptom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lifetime symptoms of alcohol dependence and treatment condition
Study: 9195351
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg i.v. propofol bolus followed by a continuous 0.5 mg/kg/hr infusion
Study: 1540108
Drug: Competing response
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Competing response therapy (performing a competing response when the urge to bite occurs)
Study: 2870990
Drug: Nifedipine combined
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine combined with propranolol (80 mg twice daily)
Study: 2870990
Drug: Nifedipine combined
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine combined with betaxolol (20 mg once daily)
Study: 2870990
Drug: Propranolol alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol alone (80 mg twice daily)
Study: 2870990
Drug: Betaxolol alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betaxolol alone (20 mg once daily)
Study: 31755587
Drug: S‐ibuprofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: S‐ibuprofen
Study: 31755587
Drug: R‐ibuprofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: R‐ibuprofen
Study: 27031099
Drug: Biweekly acupuncture
Normalized name: Biweekly Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biweekly acupuncture treatments for 6 months (group 1)
Study: 27031099
Drug: Weekly acupuncture
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly acupuncture treatments after 2 months of waitlist (group 2)
Study: 23058022
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic saline (2.7% sodium chloride solution), administered twice-daily using a disposable 20 ml syringe for 4 weeks
Study: 23058022
Drug: Normal saline,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline, administered twice-daily using a disposable 20 ml syringe for 4 weeks
Study: 22738801
Drug: Sitagliptin 100
Normalized name: SITagliptin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin 100 mg q.d.
Study: 17300595
Drug: Glipizide 5
Normalized name: glipizide 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glipizide 5 mg/day (uptitrated to a maximum of 20 mg/day)
Study: 11142674
Drug: PerioChip (chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: PerioChip (chlorhexidine gluconate 2.5 mg)
Study: 11189161
Drug: Predforte (10%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Predforte (10% prednisolone acetate) administered transnasally to the operative cavity
Study: 7706104
Drug: Dextrose-saline solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextrose-saline solution containing 1 IU per ml of heparin
Study: 7706104
Drug: Control solutions
Normalized name: Accu-Chek Comfort Curve Control Solutions
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control solutions (without heparin)
Study: 30746976
Drug: Progressive Muscle
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progressive Muscle Relaxation (PMR) with morphine 0.15 mg/kg daily in divided doses
Study: 30746976
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with morphine 0.15 mg/kg daily in divided doses
Study: 23905554
Drug: Intra-operative iv
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intra-operative iv administration of fluid boluses based on stroke volume measured by oesophageal Doppler (probe arm)
Study: 21919372
Drug: Intravenous ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketamine (0.125 mg/kg) plus clonidine (0.5 microg/kg)
Study: 21919372
Drug: Intravenous placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous placebo (sodium chloride 0.9%)
Study: 19826560
Drug: Sildenafil (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (50 mg) as add-on to standard treatment for alcohol dependence
Study: 19826560
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment for alcohol dependence without sildenafil
Study: 15280526
Drug: Oxytocin infusion
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin infusion (20 mU/min)
Study: 15280526
Drug: dDAVP (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: dDAVP (2 micro g subcutaneously)
Study: 11343530
Drug: Supportive-expressive group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive-expressive group therapy for 1 year
Study: 31537527
Drug: Plerixafor (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plerixafor (400 μg/kg/day) infused intravenously for 4 consecutive weeks starting at day 35 of concurrent chemoradiation.
Study: 31537527
Drug: Plerixafor (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plerixafor (400 μg/kg/day)
Study: 29988514
Drug: rasagiline 1
Normalized name: rasagiline 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: rasagiline 1 mg/day
Study: 29748109
Drug: rasagiline 0.5
Normalized name: rasagiline 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: rasagiline 0.5 mg/day
Study: 21971943
Drug: GB-0998 (high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: GB-0998 (high-dose intravenous immunoglobulin therapy)
Study: 19204077
Drug: Exercise on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise on prescription intervention
Study: 10812286
Drug: Naltrexone (0,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (0, 50, or 200 mg)
Study: 1854464
Drug: DuP 753
Approvals — FDA: no, EMA: no, PMDA: no
Description: DuP 753 (2.5, 5, 10, 20, and 40 mg single dose)
Study: 1854464
Drug: DuP 753
Approvals — FDA: no, EMA: no, PMDA: no
Description: DuP 753 (5, 10, 20, or 40 mg multiple dose, once daily for eight days)
Study: 6396118
Drug: Bifonazole cream
Normalized name: bifonazole
DrugBank: Bifonazole (DB04794)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bifonazole cream vehicle
Study: 28877011
Drug: Tezepelumab 70
Normalized name: Tezepelumab
DrugBank: Tezepelumab (DB15090)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tezepelumab 70 mg every 4 weeks
Study: 28877011
Drug: Tezepelumab 280
Normalized name: Tezepelumab
DrugBank: Tezepelumab (DB15090)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tezepelumab 280 mg every 2 weeks
Study: 16737850
Drug: Aspirin 325mg
Normalized name: ASPIRIN 325MG CAP
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 325mg
Study: 9432316
Drug: Omeprazole plus
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole plus amoxicillin treatment regimen
Study: 3811804
Drug: Fentanyl 0.002
Normalized name: fentanyl 0.002 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 0.002 mg/kg
Study: 3811804
Drug: Fentanyl 0.004
Normalized name: fentanyl 0.004 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 0.004 mg/kg
Study: 30075898
Drug: Dexmedetomidine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine infusion (0.5 µg/kg/h) during cardiopulmonary bypass
Study: 30075898
Drug: Propofol continuous
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol continuous intravenous infusion (50 to 70 µg/kg/min)
Study: 25411294
Drug: Non-enteric-coated (non-EC)
Normalized name: diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Non-enteric-coated (non-EC) granules (500 mg)
Study: 25411294
Drug: Non-enteric-coated (non-EC)
Normalized name: diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Non-enteric-coated (non-EC) granules (1000 mg)
Study: 25411294
Drug: Non-enteric-coated (non-EC)
Normalized name: diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Non-enteric-coated (non-EC) granules (1500 mg)
Study: 25411294
Drug: Enteric-coated (EC)
Normalized name: lipase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric-coated (EC) granules (500 mg)
Study: 25411294
Drug: Enteric-coated (EC)
Normalized name: lipase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric-coated (EC) granules (1000 mg)
Study: 25411294
Drug: Enteric-coated (EC)
Normalized name: lipase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric-coated (EC) granules (1500 mg)
Study: 25411294
Drug: FCA for
Normalized name: efgartigimod alfa-fcab Injection [Vyvgart]
Approvals — FDA: no, EMA: no, PMDA: no
Description: FCA for 1000 mg dose compared to 500 mg
Study: 25411294
Drug: FCA for
Normalized name: efgartigimod alfa-fcab Injection [Vyvgart]
Approvals — FDA: no, EMA: no, PMDA: no
Description: FCA for 1500 mg dose compared to 500 mg
Study: 22420492
Drug: DHEAS 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEAS 50 mg daily
Study: 20978193
Drug: Serum 25-hydroxyvitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum 25-hydroxyvitamin D (25(OH)D) levels <25 nmol/L
Study: 20978193
Drug: Serum 25-hydroxyvitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum 25-hydroxyvitamin D (25(OH)D) levels 25 to <37.5 nmol/L
Study: 20978193
Drug: Serum 25-hydroxyvitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum 25-hydroxyvitamin D (25(OH)D) levels 37.5 to <50 nmol/L
Study: 16037731
Drug: Gabapentin 800
Normalized name: gabapentin 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin 800 mg (in two equally divided doses)
Study: 12577433
Drug: Integrative traditional
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrative traditional Chinese and western medicine (TCM‐WM)
Study: 12577433
Drug: Chinese herbal
Normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese herbal medicine alone (TCM)
Study: 12577433
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine alone (WM)
Study: 8024076
Drug: Micronized halofantrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronized halofantrine (8 mg/kg every 6 hr in three doses)
Study: 8024076
Drug: Chloroquine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine (25 mg/kg for a 48-hr period) plus clindamycin (5 mg/kg every 12 hr in six doses)
Study: 8024076
Drug: Chloroquine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine (25 mg/kg for a 48-hr period) plus doxycycline (2 mg/kg every 12 hr in six doses)
Study: 2557685
Drug: Viscous CPRS
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Viscous CPRS containing carboxymethyl cellulose (CMC) gel for 8 hours
Study: 2557685
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group soaked in saliva-like (SL) solution
Study: 28328709
Drug: Low-fluence Q-switched
Normalized name: Chew Q
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fluence Q-switched 1,064-nm neodymium:yttrium-aluminum-garnet laser (QSNYL) weekly for 10 sessions on one cheek
Study: 21384650
Drug: 1.25 mg
Normalized name: menthol 1.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 mg droperidol intravenously before operation
Study: 15538041
Drug: Tamoxifen (TAM)
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamoxifen (TAM) 20 mg
Study: 15538041
Drug: Toremifene (TOR)
DrugBank: Toremifene (DB00539)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Toremifene (TOR) 40 mg
Study: 1617510
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (15 g/day MaxEPA, 4.5 g eicosapentaenoic and docosahexaenoic acids)
Study: 29390862
Drug: Process incentives
Normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Process incentives (earned by attending primary care visits and/or receiving prescription medication refills)
Study: 20210495
Drug: Sequential touching
Normalized name: benzethonium chloride Medicated Liquid Soap [Lysol Healthy Touch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential touching procedure for object categorization
Study: 18603890
Drug: Risperidone 4‐6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone 4‐6 mg per day
Study: 18603890
Drug: Haloperidol 10‐20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol 10‐20 mg per day
Study: 10381297
Drug: High-dose garlic
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose garlic powder dragees
Study: 8709585
Drug: Investigator-observed flushing
Normalized name: T8 Keto Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigator-observed flushing after alcohol challenge (0.75 ml/kg alcohol)
Study: 6359913
Drug: Combination ampicillin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination ampicillin, amikacin, and clindamycin (Group I)
Study: 6359913
Drug: Combination doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combination doxycycline and penicillin (Group II)
Study: 10824881
Drug: Sitzmark capsule
Normalized name: Sitzmark Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitzmark capsule administration
Study: 10824881
Drug: Plasma concentration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma concentration of acetaminophen at 45 min after oral administration
Study: 8637787
Drug: 3-week benzathine
Normalized name: etonogestrel
DrugBank: Etonogestrel (DB00294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-week benzathine penicillin G (BPG) program
Study: 8637787
Drug: 4-week benzathine
Normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-week benzathine penicillin G (BPG) program
Study: 1386223
Drug: Enoximone 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoximone 1.0 mg kg‐1 administered approximately 10 min before weaning from CPB
Study: 29095180
Drug: Topical vapocoolant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical vapocoolant spray
Study: 15645008
Drug: Alefacept (intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alefacept (intramuscular or intravenous administration)
Study: 15645008
Drug: Alefacept (second
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alefacept (second course of therapy)
Study: 11887654
Drug: Functionally loaded
Normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Functionally loaded implants (group 1)
Study: 11887654
Drug: Unloaded one-stage
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unloaded one-stage control implants (group 2)
Study: 11887654
Drug: Unloaded submerged
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unloaded submerged technique control implants (group 3)
Study: 7906578
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg dimethindene
Study: 7906578
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg dimethindene
Study: 3276336
Drug: Nystatin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nystatin (1 ml, 100,000 units/ml) administered every 8 hours until 1 week after extubation
Study: 22232848
Drug: Tablets containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets containing soy isoflavones 60 mg (genistin 30 mg + daidzin 30 mg) + calcium and vitamin D3
Study: 22232848
Drug: Tablets containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets containing soy isoflavones 60 mg (genistin 30 mg + daidzin 30 mg) + calcium and vitamin D3 + 500 million vital spores of Lactobacillus sporogenes
Study: 11076169
Drug: Empirically Supported
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empirically Supported Treatments
Study: 24903556
Drug: Prophylactic bicyclol
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic bicyclol (75 mg, oral, daily)
Study: 21422411
Drug: Control (chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (chemotherapy alone)
Study: 20685497
Drug: Basal-bolus therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal-bolus therapy (BBT) with insulin glargine once daily plus mealtime insulin lispro TID
Study: 20685497
Drug: LM75/25 (75%
Approvals — FDA: no, EMA: no, PMDA: no
Description: LM75/25 (75% insulin lispro protamine suspension and 25% insulin lispro injection) BID
Study: 20685497
Drug: LM50/50 (50%
Approvals — FDA: no, EMA: no, PMDA: no
Description: LM50/50 (50% insulin lispro protamine suspension and 50% insulin lispro injection) TID